The biopharmaceutical contract manufacturing market is projected to grow at an annualized rate of ~8%, till 2030
Owing to the ever-increasing number of start-ups that are involved in R&D of novel biologics, there is an enormous opportunity for the CMOs in this domain.
111
views

Owing to the ever-increasing number ofstart-ups that are involved in R&D of novel biologics, there is an enormousopportunity for the CMOs in this domain. It is worth emphasizing that, since2000, more than 115 new CMOs have been established in order to serve to thegrowing demand for novel biologics that have specific manufacturingrequirements. The contemporary contract services market features a mix of largeand small-sized CMOs and is characterized by multiple mergers and acquisitionsas stakeholders strive to broaden their respective service portfolios. This hasenabled several CMOs to offer end-to-end services, ranging from drugdevelopment, including preliminary R&D, preclinical and clinical trials, tocommercial scale production and regulatory filings

 

To order this 750+page report, which features 200+ figures and 250+ tables, please visit this - https://rootsanalysis.com/reports/view_document/biopharma-contract-manufacturing-market-3rd-edition-2019-2030/250.html

 

The USD 13.9 billion(by 2030) financial opportunity within the biopharmaceutical manufacturing markethas been analyzed across the following segments:

§ Commonly OutsourcedBusiness Operations

§ Active PharmaceuticalIngredients (API)

§ Finished Dosage Formulations(FDF)

§ Types of ExpressionSystem

§ Mammalian

§ Microbial

§ Others

§ Company Size

§ Small

§ Mid-Sized

§ Large and Very Large

§ Scale of Operation

§ Preclinical

§ Clinical

§ Commercial

§ Key GeographicalRegion 

§ North America

§ Europe

§ Asia-Pacific

§ Rest of theWorld 

 

The BiopharmaContract Manufacturing Market (3rdEdition), 2019-2030. report features thefollowing companies, which we identified to be key players in this domain:

§  3P Biopharmaceuticals

§  Abzena

§  Albany Molecular Research

§  BioVectra

§  BioXcellence (Boehringer Ingelheim)

§  Celonic

§  Charles River Laboratories

§  ChemPartner

§  Cobra Biologics

§  CordenPharma

§  Cytovance Biologics

§  GE Healthcare

§  Goodwin Biotechnology

§  Grand River Aseptic Manufacturing

§  IDT Biologika

§  KBI BioPharma

§  Kemwell Biopharma

§  LFB Biomanufacturing

§  Meridian Life Science

§  Patheon

§  Pfizer CentreOne

§  PX'Therapeutics

§  Samsung BioLogics

§  Sanofi, CEPiA

§  Thermo Fisher Scientific

§  Vetter Pharma International

 

 

Table of Contents

 

1. Preface

2. Executive Summary


3. Introduction

4. Competitive Landscape

5. Biopharmaceutical Contract Manufacturing inNorth America

6. Biopharmaceutical Contract Manufacturing inEurope

7. Biopharmaceutical Contract Manufacturing inAsia Pacific And the Rest of The World

8. Biopharmaceutical Contract Manufacturing inAsia Pacific And the Rest of The World

 

9. Case Study: Outsourcing of Biosimilars

10. Case Study: Comparison of SmallMolecule and   Large Molecule Drugs /Therapies

 

11. Case Study on In-House Manufacturing

12. Collaborations

13. Recent Developments

14. Capacity Analysis

 

15. Demand Analysis

 

16. Market Forecast

 

17. SWOT Analysis

 

18.  Futureof The Biopharmaceutical CMO Market

 

19. Survey Analysis

 

20. Interview Transcripts

 

21. Appendix 1: List of Non-Industry Players

 

22. Appendix 1: List of Non-Industry Players

 

23. Appendix 3: List of Companies and Organizations

 

To purchase a copy, please visit https://rootsanalysis.com/reports/view_document/biopharma-contract-manufacturing-market-3rd-edition-2019-2030/250.html

 

Contact Details

 

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com